• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Somatostatin Analogs Companies

    ID: MRFR/Pharma/7161-HCR
    140 Pages
    Rahul Gotadki
    October 2025

    Somatostatin analogs are synthetic compounds that mimic the action of somatostatin, a naturally occurring hormone that regulates various physiological functions, including the inhibition of growth hormone release. These analogs are used in the treatment of conditions such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Somatostatin Analogs Market Research Report - Global Forecast till 2034 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Somatostatin Analogs Market

    Somatostatin Analogs Key Companies

     


    Latest Somatostatin Analogs Companies Update:

    Novartis (Switzerland) Received FDA approval for Signifor® (pasireotide) LAR, a long-acting injectable for treating adults with acromegaly, offering bi-monthly dosing convenience. Continued research on Signifor® for potential applications in other hormonal disorders like Cushing's syndrome.


    Ipsen (France) Collaborated with Roche to develop and commercialize a first-in-class oral somatostatin receptor agonist for acromegaly, potentially offering a non-injectable treatment option. Focused on expanding their Somatropin portfolio and strengthening their presence in the NETs treatment market.


    Sun Pharmaceutical Industries Ltd. (India) Launched their affordable generic versions of somatostatin analogs, increasing access to treatment in resource-limited settings. Partnered with research institutions to explore the potential of somatostatin analogs for treating hormonal imbalances and metabolic disorders.


    European Neuroendocrine Tumor Society (ENETS) Updated their treatment guidelines for NETs, highlighting the evolving role of somatostatin analogs and personalized therapy approaches. Provided educational resources and patient advocacy programs to raise awareness about NETs and improve diagnosis and treatment options.


    National Cancer Institute (NCI) Funded research on the use of somatostatin analogs in combination with other therapies for cancer treatment, aiming to improve efficacy and reduce side effects. Supported studies on developing targeted delivery systems for these drugs to optimize their action and minimize systemic exposure.


    List of Somatostatin Analogs Key companies in the market


    • Novartis AG (Switzerland)




    • Ipsen Pharma (France)




    • Fresenius Kabi (Germany)




    • Peptron (South Korea)




    • Pfizer Inc. (US)




    • Teva Pharmaceuticals Inc. (Israel)